Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) insider Yuri Maricich bought 6,551 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were acquired at an average cost of $1.65 per share, for a total transaction of $10,809.15. Following the transaction, the insider directly owned 12,611 shares in the company, valued at approximately $20,808.15. This trade represents a 108.10% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

CAMP4 Therapeutics Stock Performance

NASDAQ:CAMP opened at $4.50 on Friday. The firm has a 50-day simple moving average of $4.02 and a 200-day simple moving average of $4.31. CAMP4 Therapeutics Corporation has a one year low of $1.32 and a one year high of $7.75. The firm has a market cap of $233.69 million, a P/E ratio of -1.91 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The business had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. On average, research analysts predict that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On CAMP4 Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of CAMP4 Therapeutics during the fourth quarter worth $61,000. Jefferies Financial Group Inc. purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter valued at $70,000. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth $86,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth $115,000. Finally, Goldman Sachs Group Inc. purchased a new position in CAMP4 Therapeutics during the 4th quarter worth $115,000.

Key CAMP4 Therapeutics News

Here are the key news stories impacting CAMP4 Therapeutics this week:

• Positive Sentiment: CMP-002 is advancing into human trials. CAMP4 received regulatory clearance in Australia and Argentina to begin a Phase 1/2 study of CMP-002, an antisense oligonucleotide therapy for SYNGAP1-related disorders. The double-blind, placebo-controlled trial is expected to enroll at least 30 children ages 2 to 18. This is a significant milestone because SYNGAP1-related disorder has no approved disease-modifying treatments. CAMP4 advances SYNGAP1 treatment into human trials
• Positive Sentiment: Insider buying may signal management confidence. CEO Josh Mandel-Brehm, CFO Kelly Gold, Director Richard A. Young and insider Yuri Maricich collectively bought 36,031 shares at an average price of $1.65. While the purchases were modest in dollar value, they increased the insiders’ ownership positions and may be viewed positively by investors. CAMP4 insider purchase filing
• Positive Sentiment: Recent financing improves development funding. CAMP4 raised approximately $50.1 million in the second closing of a private placement. The proceeds are intended to support CMP-002 and the company’s early-stage pipeline, with participation from institutional investors including Janus Henderson, Balyasny Asset Management, Vivo Capital and 5AM Ventures. CAMP4 private placement announcement
• Negative Sentiment: The capital raise is significantly dilutive. CAMP4 issued more than 10.7 million common shares and approximately 21.9 million pre-funded warrants at about $1.53 per share-equivalent. The expanded potential share count and discounted issuance could limit per-share upside despite extending the company’s cash runway.
• Neutral Sentiment: Clinical risk remains high. CMP-002’s move into a Phase 1/2 trial is encouraging, but the therapy is still investigational. Safety and efficacy results in humans could differ materially from preclinical findings, making future trial updates key catalysts for CAMP.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 10th. Weiss Ratings cut CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Rodman & Renshaw assumed coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Zacks Research downgraded shares of CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Seven analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.36.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.